It also highlights the potential severity of the syndrome and underlines how important it is to develop early screening strategies.

HIV Medicine

Dinh et al. have reported that, in a single centre, eight of 115 HIV-infected patients (6.9%) had unexplained noncirrhotic portal hypertension (NCPH) [1]. Their report provides further evidence that NCPH in HIV-positive patients is a vascular disease of the liver. It also highlights the potential severity of the syndrome and underlines how important it is to develop early screening strategies. Dr Dinh’s group is the tenth team worldwide to report cases of NCPH in HIV-positive patients. Undoubtedly, NCPH is an emerging disease in HIV-infected patients. Our group currently follows 21 similar patients. All were referred to our unit for unexplained abnormal liver function tests with or without portal hypertension. As did Dr Dinh, we found that the Fibroscan s was inappropriate to diagnose NCPH in HIV-positive patients. The median Fibroscan s value in our cohort was 8.3 kPa [interquartile

It also highlights the potential severity of the syndrome and underlines how important it is to develop early screening strategies.

HIV‐associated obliterative portopathy (HIV‐OP) underlies cryptogenic liver disease in HIV‐seropositive patients